R3 Vascular Email Formats

Medical Equipment Manufacturing • Mountain View, California, United States • 21-50 Employees

R3 Vascular Email Formats

R3 Vascular uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@r3vascular.com), used 50% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@r3vascular.com	50%
{first name}{last name}	johndoe@r3vascular.com	38.9%
{last name}{first initial}	doej@r3vascular.com	11.1%

Key Contacts at R3 Vascular

Orlando Marrero

Global Director Clinical Field Excellence

Jansen Gert

Director European Operations

Sarah Schermer

Director Of Clinical Operations

Kristin Ellis

Sr. Director Of Global Regulatory Affairs

Jennifer Lee

Sr Director Of Quality Assurance

Kristine Orosz

Director, Clinical Affairs

Chang Lee

Director

Company overview

Headquarters	1145 Terra Bella Ave, Mountain View, California 94043, US
Phone number	+16105856867
Website	r3vascular.com
NAICS	3391
Employees	21-50
Socials

About R3 Vascular

R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD is the narrowing or blockage of the vessels that carry blood from the heart to the legs or lower extremities; it is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can happen in any blood vessel, but it is more common in the legs than the arms. It affects 200 million people globally. Approximately 6.5 million people at the age of 40 and older in the United States have PAD. These numbers continue to rise given the increasing burden of risk factors and an aging population. If a patient has PAD, they are at risk for developing coronary artery disease and cerebrovascular disease, which could lead to a heart attack or stroke as well. The R3 Vascular BVS platform combines the best of both worlds of BTK therapy, designed to deliver the ‘stent-like’ support of a scaffold, along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.